Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Capital World Investors

Capital World Investors boosted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 16,600,525 shares of the biopharmaceutical company’s stock after acquiring an additional 92,101 shares during the period. Capital World Investors owned about 12.87% of Alnylam Pharmaceuticals worth $3,906,284,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ALNY. Larson Financial Group LLC raised its stake in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 73 shares in the last quarter. R Squared Ltd purchased a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $33,000. OFI Invest Asset Management acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $35,000. Versant Capital Management Inc raised its stake in Alnylam Pharmaceuticals by 77.6% during the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 83 shares in the last quarter. Finally, IFP Advisors Inc boosted its stake in Alnylam Pharmaceuticals by 24.2% in the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 47 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $234.56 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The company’s 50-day moving average price is $249.14 and its 200 day moving average price is $257.07. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The stock has a market cap of $30.51 billion, a price-to-earnings ratio of -108.09 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Jeffrey V. Poulton sold 967 shares of the company’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. This represents a 2.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares in the company, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock worth $19,958,097 over the last three months. 1.50% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ALNY shares. Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a report on Friday, March 21st. Morgan Stanley reduced their price objective on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating for the company in a research note on Friday, April 11th. Chardan Capital restated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the company from $280.00 to $328.00 in a research report on Monday, March 24th. Finally, Stifel Nicolaus raised their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a research report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.